An Investment Case for Ending Neglected Tropical Diseases
- PMID: 30212103
- Bookshelf ID: NBK525199
- DOI: 10.1596/978-1-4648-0524-0_ch17
An Investment Case for Ending Neglected Tropical Diseases
Excerpt
The neglected tropical diseases (NTDs) affect more than 1 billion of the poorest and most marginalized people of the world. These infections are a consequence of the environmental and socioeconomic conditions in which the poor live, and the ill health and disability they cause are a primary factor locking the poor into poverty. They are diseases of the most neglected people who live in countries that lack the basic resources to control them. Yet this chapter demonstrates that the tools to end this neglect already exist, and that there are compelling economic arguments that ending these diseases would be one of the most cost-effective of global public health programs.
The NTD concept was developed to draw attention to this opportunity that was overlooked by the Millennium Development Goals (MDGs). At least 18 diseases are recognized as NTDs by World Health Assembly resolutions; the latest addition is mycetoma (WHO 2013, 2016). The World Health Organization (WHO) has set specific targets for control, elimination, and eradication of a subset of these diseases (table 17.1). These are the NTDs that we focus on in this chapter. The end of NTDs is now firmly embedded within the Sustainable Development Goals (SDGs) for 2030, under target 3.3, reflecting the promise to “leave no one behind.”
This chapter reaffirms the case that NTDs account for a significant and unfairly distributed global disease burden, cost-effective interventions exist to reduce that burden, these interventions are affordable, and they are good investments in universal health coverage and social protection. It builds on the second edition of the Disease Control Priorities (DCP2) project (Hotez and others 2006) with new data and analysis. It also takes into account new strategies and tools that have been introduced since 2006 and the increasingly ambitious elimination and eradication targets for individual diseases that have emerged since 2012, including the unprecedented donation by the pharmaceutical industry under the London Declaration of more than a billion medicines annually to treat nine of the most important NTDs. Finally, it helps provide a longer-term perspective on SDG target 3.3 and the 2030 goals.
This chapter is structured around three key NTD interventions, rather than individual NTDs, in recognition of the increasingly integrated delivery of interventions to the poorest, most remote, and otherwise most marginalized communities of the world. These interventions are as follows:
Preventive chemotherapy by mass drug administration
Innovative and intensified disease management
Vector ecology and management.
For simplicity of analysis, we focus on a subset of the NTDs recognized by the WHO. We do not provide a full analysis of veterinary public health interventions against zoonotic NTDs or of water, sanitation, and hygiene (WASH). These conditions are beyond the scope of this chapter, but WASH is addressed in chapter 9 in volume 7 of the third edition of Disease Control Priorities (Hutton and Chase 2017). Chapter 13 in volume 8 (Bundy and others 2017) discusses mass deworming programs, and chapter 29 (Ahuja and others 2017) in volume 8 analyzes the economics of such programs.
© 2017 International Bank for Reconstruction and Development / The World Bank.
Sections
- Introduction
- Burden of NTDs
- Proof of Concept for Ending NTDs
- Interventions to End NTDs
- Cost and Cost-Effectiveness of Interventions to End NTDs
- Fairness of Interventions to End NTDs
- Targets for the Scale-Up of Interventions to End NTDs
- Return on Investments to End NTDs
- Place of NTDS in the Grand Convergence
- Conclusions
- Note
- References
Similar articles
-
Tuberculosis.In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11. PMID: 30212088 Free Books & Documents. Review.
-
Neglected tropical diseases: an effective global response to local poverty-related disease priorities.Infect Dis Poverty. 2020 Jan 28;9(1):10. doi: 10.1186/s40249-020-0630-9. Infect Dis Poverty. 2020. PMID: 31987053 Free PMC article. Review.
-
Impact of COVID-19 on the neglected tropical diseases: a scoping review.Infect Dis Poverty. 2024 Jul 29;13(1):55. doi: 10.1186/s40249-024-01223-2. Infect Dis Poverty. 2024. PMID: 39075616 Free PMC article. Review.
-
The cross-cutting contribution of the end of neglected tropical diseases to the sustainable development goals.Infect Dis Poverty. 2017 Apr 4;6(1):73. doi: 10.1186/s40249-017-0288-0. Infect Dis Poverty. 2017. PMID: 28372566 Free PMC article. Review.
-
Leaving no one behind: a neglected tropical disease indicator and tracers for the Sustainable Development Goals.Int Health. 2016 Mar;8 Suppl 1(Suppl 1):i15-8. doi: 10.1093/inthealth/ihw002. Int Health. 2016. PMID: 26940304 Free PMC article.
References
-
- Ahuja A, Baird S, Hicks J H, Kremer M, Miguel E, others. 2015. “When Should Governments Subsidize Health? The Case of Mass Deworming.” World Bank Economic Review 29 (Suppl 1): S9–24.
-
- Ahuja A, Baird S, Hicks J H, Kremer M, Miguel E. 2017. “The Economics of Mass Deworming Programs.” In Disease Control Priorities (third edition): Volume 8, Child and Adolescent Health and Development, edited by Bundy D A P, Silva N de, Horton S, Jamison D T, Patton G C. Washington, DC: World Bank.
-
- Anoopa S D, Bern C, Varghese B, Chowdhury R, Haque R, others. 2006. “The Economic Impact of Visceral Leishmaniasis on Households in Bangladesh.” Tropical Medicine and International Health 11 (5): 757–64. - PubMed
-
- Baltussen R, Sylla M, Frick K D, Mariotti S P. 2005. “Cost-Effectiveness of Trachoma Control in Seven World Regions.” Ophthalmic Epidemiology 12 (2): 91–101. - PubMed
Publication types
LinkOut - more resources
Full Text Sources